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ABSTRACT
The etiology of Crohn’s disease (CD) is multifactorial. Bacterial and fungal microbiota are involved in 
the onset and/or progression of the disease. A bacterial dysbiosis in CD patients is accepted; 
however, less is known about the mycobiome and the relationships between the two communities. 
We investigated the interkingdom relationships, their metabolic consequences, and the changes in 
the fungal community during relapse and remission in CD.
Two cohorts were evaluated: a British cohort (n = 63) comprising CD and ulcerative colitis 
patients, and controls. The fungal and bacterial communities of biopsy and fecal samples were 
analyzed, with the fecal volatiles; datasets were also integrated; and a Dutch cohort (n = 41) 
comprising CD patients and healthy controls was analyzed for stability of the gut mycobiome.
A dysbiosis of the bacterial community was observed in biopsies and stool. Results suggest 
Bacteroides is likely key in CD and may modulate Candida colonization. A dysbiosis of the fungal 
community was observed only in the Dutch cohort; Malassezia and Candida were increased in 
patients taking immunosuppressants. Longitudinal analysis showed an increase in Cyberlindnera in 
relapse. Saccharomyces was dominant in all fecal samples, but not in biopsies, some of which did 
not yield fungal reads; amino acid degradation was the main metabolic change associated with CD 
and both bacteria and fungi might be implicated.
We have shown that Bacteroides and yeasts may play a role in CD; understanding their role and 
relationship in the disease would shed new light on the development and treatment of CD.
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Introduction
The etiology of inflammatory bowel disease (IBD) is 
multifactorial. There are perturbations of immune 
regulation and the microbiota,1 and over 200 risk 
alleles.2 The incidence of IBD has increased with 
Westernization: in countries where IBD was rare, 
the incidence is approaching that in Europe.3 
Environmental factors influence the intestinal 
microbiota.4 Many observations suggest a link 
between fungi and IBD. There are increased fungal 
metabolites in the feces of patients with active 
Crohn’s disease (CD).5 Anti-Saccharomyces cerevi-
siae antibodies (ASCA) in CD patients are linked 
with genetic mutations involved in the immune 
response to fungi and IBD.6 Many studies have 
reported changes in the bacterial community in 
IBD7,8 but fewer have looked at the role of fungi in 
IBD.9–19 In general, the mycobiome of IBD patients 
contains significantly more Candida than that of 
healthy controls11–14 and an increase of Malassezia 
has been reported in CD patients.18 A recent study 
has also shown that Debaryomyces (a yeast com-
monly found in food products) prevents healing in 
the inflamed mucosa of CD patients.20
Murine studies support a role for fungi in IBD. 
Iliev et al.21 demonstrated that ASCA increases in 
a murine colitis model induced by ingestion of 
dextran sodium sulfate (DSS). Analysis of the fecal 
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mycobiome showed that C. tropicalis dominated the 
community in DSS-treated mice, and nonpathogenic 
Saccharomyces was decreased. Tissue damage appears 
to be regulated by Dectin-1, a C-type lectin receptor 
used for fungal cell wall recognition. Increased sus-
ceptibility to DSS and increased fungal burden 
(Candida) was also observed in Dectin-3-deficient 
mice.22 Susceptibility to colitis in Dectin-1 deficient 
mice was ameliorated by the antifungal agent fluco-
nazole. This is controversial because broad-spectrum 
antifungals may exacerbate colitis23,24 and increase 
bacterial diversity, resulting in increases of pathogenic 
species.23 A study on CX3CR1+ expressing mono-
nuclear phagocytes (MNPs) reported that these are 
involved in the immune response to intestinal fungi; 
selective depletion of intestinal CX3CR1+ MNPs in 
mice treated with DSS was associated with severe 
colitis (ameliorated by the use of fluconazole); and 
an impaired immune response to fungi in CD subjects 
with a polymorphism of CX3CR1 gene.25 These stu-
dies imply that fungi have a complex role in IBD. 
They also indicate an interaction between fungi and 
bacteria. Interkingdom communications in the intest-
inal environment, where organisms are physically 
closely located, appears intuitive. Indeed, both 
positive13,26 and negative27 connections between bac-
teria and fungi have been reported (summarized in28).
Microbiome studies are typically costly and 
incur confounding technical challenges. The fecal 
volatile metabolome is relatively inexpensive to 
investigate. Biomarker amplicon sequencing 
focuses on the composition of a community. The 
metabolome can potentially provide a clearer indi-
cation of the functional activity of a microbial com-
munity. We have undertaken metabolomics studies 
of volatile compounds from feces of patients with 
IBD and other disorders,29,30 and reported the 
changes in volatile organic compounds (VOCs) 
associated with CD and ulcerative colitis (UC).5 
Some of these metabolites appeared to be of fungal 
origin5 and this led us to investigate the fecal myco-
biome of patients with IBD.
The need to integrate multiple high-dimensional 
biology approaches to further understanding of the 
function of gut microbiota in IBD has been 
proposed.1 A recent study showed the potential of 
combining omics approach to integrate metabolo-
mics and microbiome results.31 Other studies have 
investigated the bacterial and fungal community of 
the same cohort (e.g.12,13), and recently a study 
combined metabolomics data to bacterial and fun-
gal community datasets.19 In here, a similar multi- 
omics approach was undertaken to explore the 
underlying biological mechanisms, using an opti-
mized genomic analysis of the fecal mycobiome of 
patients with IBD32 and a dedicated tool to inte-
grate datasets.33
This study investigated the hypothesis that 
interactions between fungal and bacterial commu-
nities and consequential metabolic changes would 
be observed in patients with CD, and that the 
mycobiome would evolve during periods of dis-
ease activity and remission. Specifically, we per-
formed a cross-sectional analysis of a British 
cohort of 23 patients with CD, 20 with UC and 
20 non-IBD controls. In addition, we analyzed the 
fungal community longitudinally, in a Dutch 
cohort of CD patients (n = 26), sampled multiple 
times in relapse and remission, and healthy con-
trols (n = 15). Analysis of the bacterial community 
of the Dutch cohort was beyond the scope of this 
work and it has been already published in 
a separate study.34 We investigated the fecal 
microbiome samples from both cohorts of IBD 
patients and the mucosal microbiome and fecal 
volatile metabolome from the British cohort. 




The demographic and clinical characteristics of the 
British cohort are given in Table 1. Stool samples 
from 63 subjects were analyzed. For a subset of 
patients (n = 41), biopsies from the ileum (n = 34) 
and/or the colon (n = 80) were analyzed. Active 
disease was defined based on fecal calprotectin 
(>200 μg/g) for both CD and UC.
For the Dutch cohort, 53 samples were collected 
from 26 CD patients during relapse and remission. 
Activity of CD was based on fecal calprotectin as 
described in Tedjo et al.34 Stool was also donated by 
15 healthy individuals, 14 of these were sampled 
twice on different occasions. Demographic and 
clinical characteristics for this cohort are presented 
in Table 2 and 3.
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Bacterial microbiome of the British cohort
The bacterial community of stool and biopsy sam-
ples was analyzed. After filtering, the median num-
ber of reads per sample was 100,905.5 (min 4401, 
max 2,511,360 reads). Alpha diversity, which looks 
at and compares groups in terms of number for 
species and their abundance, (Figure 1-A) was 
lower in CD (biopsy and stool) compared with 
control and/or UC, but this was not observed 
when comparing controls and UC patients.
Table 1. Demographic of the participants from the British cohort. Continuous variables are expressed as median (interquartile range, 
IQR), the other variables (sex, smoking, distribution and medications use) are shown as n and percentage. L1 = ileal CD, L2 = colonic 
CD, L3 = ileo-colonic distribution of CD. BMI = body mass index, TI = terminal ileum, TC = transverse colon, SC = sigmoid colon, 
bdl = below detection limit. * refers to the whole cohort of 63 subjects. ** use of antibacterial drugs in the 3 months prior collection of 
the sample.
CROHN’S DISEASE ULCERATIVE COLITIS CONTROLS 
(NON-IBD)Activity Status Remission Active Remission Active
Subjects – Stool n = 12 n = 11 n = 11 n = 9 n = 20
Sex F = 9 (75%) F = 5 (45.4%) F = 5 (45.4%) F = 3 (33.3%) F = 9 (45%)
Age (median, IQR) 33.5 (17) 32 (31) 47 (29) 50 (12) 55 (21)
BMI (median, IQR) 25 (6) 22 (5) 27 (4) 26.215 (6.5) 28.28 (6)
Smoking 
(Yes or previous)
8 (66.7%) 4 (36.4%) 4 (36.4%) 4 (44.4%) 8 (40%)
Fecal calprotectin (μg/g) (median) 84 376 49 368 42
Subjects – Biopsies n = 8 n = 10 n = 8 n = 4 n = 11
Sex F = 5 (62.5%) F = 5 (50%) F = 3 (37.5%) F = 2 (50%) F = 7 (63.6%)
Age (median, IQR) 33.5 (14.5) 36.5 (29) 45.5 (18.5) 52.5 (16) 56 (26)
BMI (median, IQR) 25 (3) 22 (5) 27.955 (3) 24.43 (6) 26.33 (5)
Smoking status 
(Yes/previous)
3 (37.5%) 3 (30%) 3 (37.5%) 1 (25%) 5 (45.4%)
Disease distribution L2 = 4 (50%) 
L3 = 4 (50%)
L1 = 4 (40%) 
L3 = 6 (60%)
- - -
Biopsy site TI = 8 
TC = 8 
SC = 7
TI = 7 
TC = 10 
SC = 10
TI = 8 
TC = 8 
SC = 8
TI = 3 
TC = 4 
SC = 4
TI = 8 
TC = 11 
SC = 10
Subjects – Plasma n = 8 n = 8 n = 10 n = 8 n = 14









Antibiotics** n = 1 (8.33%) n = 2 (18.18%) n = 0 n = 0 n = 1 (5%)
Mesalamine n = 2 (16.67%) n = 2 (18.18%) n = 9 (81.81%) n = 6 (66.67%) n = 0
Glucocorticoids n = 1 (8.33%) n = 2 (18.18%) n = 0 n = 1 (11.11%) n = 2 (10%)
Immunosuppressants n = 2 (16.67%) n = 4 (36.36%) n = 1 (9.09%) n = 3 (33.33%) n = 1 (5%)
Biologics n = 0 n = 3 (27.27%) n = 2 (18.18%) n = 2 (22.22%) n = 0
Selective Serotinin Reuptake Inhibitor n = 1 (8.33%) n = 1 (9.09%) n = 1 (9.09%) n = 0 n = 3 (15%)
Proton pump inhibitor n = 2 (16.67%) n = 3 (27.27%) n = 2 (18.18%) n = 0 n = 5 (25%)
Table 2. Demographic of the participants from the Dutch cohort 
at baseline (n = 41). Continuous variables are expressed as 
median (interquartile range, IQR), the other variables (sex, smok-
ing, status and distribution) are shown as n and percentage. 
L1 = ileal CD, L2 = colonic CD, L3 = ileo-colonic distribution of 
CD.
CROHN’S DISEASE HEALTHY CONTROLS
Subjects n = 26 n = 15
Sex F = 14 (53.8%) F = 7 (46.7%)
Age (median, IQR) 43.5 (34) 25 (7)
Smoking status 
(Yes/previous)
14 (53.8%) 2 (13.3%)
Status Active = 8 (30.8%) 
Remission = 18 (69.2%)
-
Distribution L1 = 9 (34.6%) 
L2 = 7 (36.9%) 
L3 = 9 (34.6%)
-
Table 3. Medication use and clinical data (Dutch cohort) for 
remission and active samples (n = 44). T1 = time point 1, 
T2 = time point 2. Continuous variables are expressed as median 
(interquartile range, IQR), the other variables (distribution and 
medications use) are shown as n and percentage. L1 = ileal, 
L2 = colonic, L3 = ileo-colonic distribution of CD. 
CRP = C-reactive protein. * use of antibiotics in the 2 months 







Distribution L1 = 10 
(45.4%) 
L2 = 5 
(22.7%) 
L3 = 7 
(31.8%)
L1 = 5 
(41.67%) 
L2 = 2 
(16.67%) 
L3 = 5 
(41.67%)
L1 = 5 
(50%) 
L2 = 3 
(30%) 
L3 = 2 
(20%)
Fecal calprotectin (μg/g) 
(median, IQR)
43 (45.5) 38.5 (62.5) 252 (80)
Serum CRP 1.9 (1.75) 1.5 (1.3) 3.5 (2.8)
Medications
Mesalamine n = 4 (18.2%) n = 1 (8.33%) n = 1 (10%)
Immunosuppressants n = 9 (40.9%) n = 5 (41.67%) n = 5 (50%)
Biologics n = 13 (59.1%) n = 5 (41.67%) n = 8 (80%)
Proton pump inhibitor n = 8 (36.4%) n = 4 (33.33%) n = 4 (40%)
Antibiotics* n = 1 (4.5%) n = 1 (8.33%) n = 0
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Sample similarity was explored using beta diver-
sity, that is, how similar samples were in terms of 
distribution of taxa (using Bray-curtis distance), or 
phylogeny (unweighted Unifrac distance), or 
a combination of both (weighted Unifrac distance) 
(Figure 1-B). Permutational multivariate analysis of 
variance (PERMANOVA) analysis (Figure 1-B2) 
showed that the main sources of variability in com-
munity structure were the patient ID, followed by 
the diagnosis and the site/specimen type. Samples 
clustered according to the diagnosis (Figure 1-B1) 
and the distribution of the disease (Figure 1-B3), 
with clear segregation between patients with exclu-
sively ileal or colonic disease. PERMANOVA ana-
lysis was also performed for all the predictors 
(Supplemental material 2, Table S1). Significant 
variability in community structure was found for 
age, BMI, sex, ASCA, antibiotics, mesalamine- and 
immunosuppressant-use. Significant results were 
obtained for the use of antibiotics, but no sample 
was excluded, as none was an outlier (see 
Supplemental material 3, Figure S1).
Taxa differential analysis (enrichment analysis to 
highlight taxa that are log2 fold different) results 
are shown in Figure 2. Operational taxonomy units 
(OTUs) assigned to Lachnoclostridium were 
increased in all mucosa sites and the stool in CD. 
Some OTUs assigned to Bacteroides were increased 
in the mucosa in CD, whereas others were 
decreased. Bacteroides was decreased in stool sam-
ples in CD. The butyrate producers 
Faecalibacterium and Roseburia were depleted in 
Figure 1. Alpha and Beta diversity results of the bacterial gut microbiome (British cohort). A1 to A4: Alpha diversity of the bacterial 
microbiome from the four specimen types: terminal ileum, transverse colon, sigmoid colon and stool. Samples were grouped according 
to diagnosis: Crohn’s disease (CD), ulcerative colitis (UC) and Controls. Three indices were considered: Fisher alpha, richness and 
Shannon index. Pair-wise ANOVA was calculated between the groups (CD, UC and Controls) and if significant, stars are shown on top (* 
p < .05, ** p < .01 and *** p < .001). B1 to B4: Nonmetric distance scaling (NMDS) showing clustering of samples. To produce these 
charts, samples (n = 176) from patients for which terminal ileum (TI), transverse colon (TC), sigmoid colon (SC) and stool were available. 
In B3 only samples from CD patients (n = 72) were considered. The charts were produced using Bray–Curtis (Operational taxonomy 
units (OTUs) level). The ellipses represent 95% confidence interval of standard error for a given group. The table in B2 summarizes 
permutational multivariate analysis of variance (PERMANOVA) results for all the distances, Bray–Curtis, unweighted UniFrac (UniFrac) 
and weighted (W. UniFrac). R2 refers to the percentage of variability among samples’ microbiome that can be explained by that factor/ 
metadata.
e1930871-4 A. FRAU ET AL.
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CD in most of the sites analyzed. The same was 
observed for Methanobrevibacter.
Taxonomy summary and environmental filter-
ing results are shown in Supplemental material 3, 
Figure S2. Environmental filtering assumes that 
microbial communities under a stronger environ-
mental pressure are more phylogenetically similar 
(clustered) either on a global scale (net relatedness 
index, NRI) or in terms of terminal clades (nearest 
taxon index, NTI), as closer taxa phylogenies are 
likely to share similar functionality. Interestingly, 
CD patients had higher values of both phylogenetic 
alpha diversity measures NRI and NTI than con-
trols (stool and colon), and UC (all sites) implying 
that CD creates an environmental pressure on the 
microbiota (Supplemental material 3, Figure S2).
BV-STEP routine, as used previously by the 
authors,35–37 was applied to reduce the complexity 
of the OTU table and find subsets of relevant 
OTUs. This algorithm calculates distances (Bray– 
Figure 2. A Taxa differential analysis results and phylogenetic tree of the bacterial gut microbiome (British cohort). A Taxa differential 
analysis comparing CD and control samples. Results are presented according to sample type: A1: Terminal Ileum (TI); A2: Transverse 
colon (TC); A3: sigmoid colon (SC); A4: stool. The bar charts show Log2 fold change in abundance between groups (y axis on the left 
and dark gray bar) and the mean abundance across all the samples (y axis on the right and light gray bar). Taxa increased in CD 
patients have bars with a red border, meanwhile taxa increased in controls have bars with a blue border. A subset of the most 
important and abundant OTUs selected using Random Forest are shown; these are taxa that allowed to achieve a 70–80% of accuracy 
in discriminating between groups are shown (details are in Supplemental material 1). A complete list of taxa that had significant 
different abundance, and further details, including adjusted p values, is in Supplemental material 4. B Phylogenetic tree of bacterial 
16S rRNA OTUs. Samples (n = 176) were from TI, TC, SC and stool (British cohort) with the Bacteroides branch magnified. The tree was 
visualized with EvolView, which was also used to add the heatmap. The * indicates OTUs that were increased in the groups analyzed or 
selected in the subsets (BV-STEP analysis) that best correlated with the whole OTU table.
Figure 3. Fungal microbiome results (British cohort). Samples were from stool (n = 63) and biopsies (n = 81): terminal ileum, transverse 
colon and sigmoid colon. A Alpha diversity (richness) of samples from the mucosa (A1) and stool (A2). Samples were grouped 
according to diagnosis: Crohn’s disease (CD), ulcerative colitis (UC) and Controls. Pair-wise ANOVA was calculated between the groups 
(CD, UC and Controls) but was not significant. B Beta diversity analysis of the fungal microbiome from the biopsy samples. B1 to B3: 
Nonmetric distance scaling (NMDS) showing clustering of samples. B1 compares samples according to diagnosis. In B2 only samples 
from CD patients were considered, meanwhile inflammatory bowel disease (IBD) active vs Control samples are compared in B3. 
A dashed line links samples from the same patient. The charts were produced using unweighted UniFrac (Operational taxonomy units 
(OTUs) level). The ellipses represent 95% confidence interval of standard error for a given group. The table in B4 summarizes 
permutational multivariate analysis of variance (PERMANOVA) results for distances for which significant results were obtained. R2 
refers to the percentage of variability among samples’ microbiome that can be explained by that factor/metadata. Only significant 
comparisons are presented (* p < .05, ** p < .01 and *** p < .001).
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Curtis) between samples by permuting through the 
subsets of OTUs in such a way that the distances 
(using fewer OTUs) remain roughly conserved in 
beta diversity space with the distances between 
samples using all the OTUs, that is, the correlation 
is maximized between the distances obtained from 
reduced subset of OTUs with that of full set of 
OTUs. PERMANOVA was used on the subsets 
obtained to see if these have discriminatory 
power, and whether calprotectin (an indicator of 
intestinal inflammation) could explain the variabil-
ity of microbial communities based on these 
Figure 4. Fungal microbiome results (British cohort). Samples were from stool (n = 63) and biopsies (n = 81): terminal ileum, transverse 
colon and sigmoid colon. A Taxonomy summary for stool at genus level. B Taxa differential analysis (CD vs Controls) at genus level. 
Results are presented according to sample type: B1: Terminal Ileum samples; B2: Transverse colon samples; B3: sigmoid colon samples; 
B4: stool. The bar charts show Log2 fold change in abundance between groups (y axis on the left and dark gray bar) and the mean 
abundance across all the samples (y axis on the right and light gray bar). Taxa increased in CD patients have bars with a red border, 
meanwhile taxa increased in controls have bars with a blue border. Detail of these results, including adjusted p values, is in 
Supplemental material 5.
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subsets (Supplemental material 2, Table S2). Seven 
subsets were found with the OTU table from stool, 
with a correlation (R) > 0.6. Up to 16% of the 
variability of five of these subsets could be 
explained by calprotectin. Similar subsets were 
obtained for the terminal ileum, transverse and 
sigmoid colon; Bacteroides OTUs were often 
found in the mucosa subsets, along with butyrate 
producers (Dorea, Roseburia, Faecalibacterium and 
Blautia) and Escherichia-Shigella (see Supplemental 
material 2, Table S2).
Taxa differential analysis and BV-STEP showed 
that some Bacteroides OTUs were more relevant in 
CD, whilst others were more abundant in controls. 
In order to understand whether the OTUs 
increased in one group (CD or control) or site 
(mucosa sites or stool) where different from those 
increased in the others, further analysis was carried 
out. The Evolview website was used to visualize the 
phylogenetic tree with the Bacteroides branch 
(Figure 2-C) isolated and magnified. These results 
suggested that these OTUs were phylogenetically 
different. These OTUs were subsequently blasted 
against NCBI NT database (see methods). OTUs 
that were significantly increased in CD cohort were 
assigned to B. ovatus (OTU234 and OTU3322) 
(terminal ileum) and B. thetaiotaomicron 
(OTU2656 and OTU2227) (transverse colon). 
B. eggerthii (OTU268) was significantly more abun-
dant in controls (TI, TC and stool). Other relevant 
OTUs (OTU2191, OTU2703, OTU2 and OTU28) 
were assigned to B. vulgatus. These were increased 
both in CD and controls compared to UC.
Fungal microbiome of the British cohort
The majority of the 63 stool samples provided fungal 
reads, suggesting a strong fungal 18S rRNA signal. 
After filtering, the median number of reads per sam-
ple was 143,310 (min 3,480, max 975,102 reads). All 
biopsy samples (n = 119) were sequenced for fungal 
18S rRNA; 38 yielded a low number of, or mainly 
spurious, reads and were discarded during analysis 
(see Methods and Supplemental material 3, Figure 
S3), leaving 81 samples. After filtering, the median 
number of reads per sample was 54,614 (min 1,314, 
max 225,544 reads).
Alpha diversity results describing microbial rich-
ness and diversity (Figure 3-A1 and A2) found few 
(<20) OTUs per sample, with no significant differ-
ences between the three groups (controls, CD and 
UC) for Richness and the two indices (Shannon and 
Fisher Alpha). Beta diversity results revealed no inher-
ent clustering based on stool samples. Analysis of all 
biopsy samples, using PERMANOVA analysis with 
unweighted UniFrac distance, found that the patient 
ID, diagnosis and CD status (relapse vs remission) 
explained the variability of the microbial community 
(Figure 3-B1, B2 and table in B4). A difference in 
community signature was observed between IBD 
(CD and UC) in relapse and controls (Figure 3-B3). 
No significant difference was observed in alpha diver-
sity and minimal change in taxa differential analysis 
between these groups.
PERMANOVA analysis (Supplemental material 2, 
Table S3) was also performed for clinical/demo-
graphic metadata as previously described. Samples 
from all the sites were analyzed together (separately 
no significant results were obtained for most compar-
ison), many parameters gave significant results (i.e. 
age, sex, smoking, calprotectin and medications); for 
most of these the R2 was low (up to 3%), non-metric 
multidimensional scaling (NMDS) charts were pro-
duced for all metadata that gave significant results 
(Supplemental material 3, Figure S4). These did not 
show any clustering. BV-STEP analysis was per-
formed, but no significant results were obtained.
Taxonomy summary of dominant taxa in stool 
samples (Figure 4-A) showed that Saccharomyces 
was the most common genus: it was present in every 
stool sample and was the most abundant genus in 
biopsies, but it is not present in every mucosa sample 
(Supplemental material 3, Figure S5). Other common 
genera were Candida and Malassezia. Taxa differential 
analysis (Figure 4-B1 to B4, details in Supplemental 
material 5) show that Candida was reduced in CD in 
the sigmoid colon and stool compared with controls; 
Malassezia increased in the transverse colon and stool 
of CD patients but was reduced in the ileum in the 
same patients. However, Malassezia abundance in 
stool was rather low (Figures 4B-4), and as the bar 
chart in Figure 4a and Supplemental material 8 show, 
it was observed only in a few samples.
Fungal microbiome of the Dutch cohort
The median number of reads per sample, after 
filtering, was 109,459.5 (min 5822, max 392,780 
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reads). Initial analysis compared baseline samples 
from healthy controls and CD patients (cross- 
sectional analysis) (Figure 5). Subsequently, long-
itudinal analysis enabled comparison of relapse and 
remission in the same patients (Figure 6). The 
comparison of healthy controls and CD patients 
at baseline showed that there was a dysbiosis in 
the fungal community in CD. This was character-
ized by a reduction in diversity (Figure 5-A); beta 
diversity analysis also showed a separation of sam-
ples between CD and controls (Figure 5-B1). The 
number of OTUs in these samples was low, similar 
to the British cohort. Saccharomyces was again the 
most abundant genus (Figure 5C) followed by 
Candida. PERMANOVA analysis, considering 
demographic and clinical data, gave significant 
results (Supplemental material 2, Table S4) for 
two medications: biologics and immunosuppres-
sants. Clustering analysis (Principal Coordinate 
Analysis (PCoA)) showed that the samples of 
patients receiving these treatments formed 
a separate cluster (Figure 5-B2 and B3). Taxa differ-
ential analyses showed that Saccharomyces was sig-
nificantly higher in healthy controls and Candida in 
CD patients, Malassezia was also increased in sub-
jects with CD (Figure 5-D1, details in Supplemental 
material 6). Patients who were taking immunosup-
pressants had an increase of Candida and 
Malassezia (Figure 5-D2). As observed in the 
British cohort, Malassezia abundance was low, 
and it was prevalent only in a few samples (Figure 
5c, Supplemental material 8).
Stability analysis compared two time points for 
three different groups: 1) RA patients that were in 
Figure 5. Results of the fungal microbiome analysis of the Dutch cohort comparing baseline samples (time point 1). Samples were 
grouped according to diagnosis: Crohn’s disease (CD, n = 26) and healthy controls (HC, n = 15). A Alpha diversity results (Operational 
taxonomy units (OTUs) level), three indices were considered: richness, Fisher alpha and Shannon. B Beta diversity results (OTUs level), 
clustering was made with Principal Coordinate Analysis (PCoA) using unweighted UniFrac distance. B1 samples grouped according to 
diagnosis. B2 yes = individuals given immunosuppressants (n = 11), no = individuals not taking the medication (n = 29). B3 
yes = individuals given biologics (n = 12), no = individuals not taking the medication (n = 28). Permutational multivariate analysis 
of variance (PERMANOVA) results (R2 and p value) are reported in the bottom of each chart. C Taxonomy summary at genus level. 
D Taxa differential analysis, bar charts showing the OTUs that were significantly different between the two groups (HC and CD) and CD 
patients on Immunosuppressant (yes) vs CD patients that were not given the medication (no). The bar charts show Log2 fold change in 
abundance between groups (y axis on the left and dark gray bar) and the mean abundance across all the samples (y axis on the right 
and light gray bar). Detail of these results, including adjusted p values, is in Supplemental material 6.
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remission at time point 1 and in relapse at time 
point 2, 2) RR patients that were in remission at 
both time points and 3) HC healthy controls at two 
time points (T1 and T2) (Figure 6). Delta alpha 
diversity (Figure 6-A) calculated the changes in 
alpha diversity (delta) for each individual and the 
average changes were then compared between 
groups. This analysis shows that these estimates 
were stable over time for all groups. Overall, the 
community was mildly conserved within the same 
individual, as the ID explains almost 60% of the 
variability among samples (PERMANOVA results 
in Figure 6-B). Beta diversity estimates, describing 
the stability of the community during time within 
Figure 6. Results of the longitudinal analysis of the Dutch cohort; HC: T1 vs T2. RA: from remission to active, RR: stayed in remission. 
A Delta alpha diversity, average of changes in alpha diversity for each sample in each group. B Beta diversity (Principal Coordinate 
Analysis) describes the differences among samples/groups considering the species observed and their phylogeny (unweighted UniFrac 
distance). The link between points indicates that the two samples are from the same subject. The ellipses represent 95% confidence 
interval of standard error for a given group. PERMANOVA results (R2 and p value) are reported in the bottom of the PCoa chart. C Beta 
diversity distance describes the stability of the community during time within the same subject. A higher value indicates that there is 
less stability during time. Significant results are presented with an * (* p < .05, ** p < .01 and *** p < .001). D Beta-dispersion box plot 
comparing variance of samples from the group centroid, RA vs RR. E Taxa differential analysis, showing OTUs that were significantly 
different between RA and RR at time point 1 (E1) and RA and RR at time point 2 (E2). The bar charts show Log2 fold change in 
abundance between groups (y axis on the left and dark gray bar) and the mean abundance across all the samples (y axis on the right 
and light gray bar). Detail of these results, including adjusted p values, is in Supplemental material 6.
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the same subject (Figure 6-C), also showed that the 
community of healthy individuals was more stable 
over time, and this is significant when comparing 
HC and RR. Beta diversity analysis (Figure 6-B), 
show that RA samples cluster tightly compared to 
RR and HC, suggesting that RA samples are similar 
to one another. This was also confirmed by the 
beta-dispersion analysis of the spread of samples 
(Figure 6-D), which showed that RA samples have 
a significantly smaller variance when compared 
to RR.
Taxa differential analysis showed that at T1 
a Capnodiales OTU was more abundant in RA, 
but it was more abundant in RR at T2 (Figure 
6-E1 and E2). Cyberlindnera was increased during 
relapse at T2 (Figure 6-E2). This suggests that 
Capnodiales may be associated with remission and 
that Cyberlindnera may thrive during 
inflammation.
Metabolomic profiles of the British cohort
The metabolomics profiles of CD patients and 
healthy controls, from the British cohort, were 
compared using PLS-DA (partial least-squares pro-
jection to latent structures-discriminant analysis): 
CD patients formed a separate cluster 
(Supplemental material 3, Figure S6-A). Part of 
this separation was driven by two compounds 
related to fungal metabolism: 3,7-dimethylocta- 
1,6-dien-3-ol and octanal;5,38–40 although these 
may also be derived from bacteria. Branched 
chain fatty acids (BCFA), that is, 3-methylbutanoic 
acid, 2-methylpropanoic acid and 2-methylbuta-
noic acid, were also increased in CD, along with 
esters (propyl propanoate, 2-methylpropyl pro-
panoate and 2-methylpropyl butanoate), butanoic 
acid, nonanal and indole (Supplemental material 3, 
Figure S6-B).
Multi-omics analysis of the British cohort data
VOCs, bacterial and fungi microbiome data from 
stool were integrated with the DIABLO algorithm, 
a multi-group derivative of sparse PLS-DA. The 
DIABLO algorithm reduces each multivariate data-
set of multiple features (VOCs, bacteria, and fungi) 
to components (derived by a linear combination of 
features in these multi-omics dataset) such that the 
first few components can be used to explain the 
majority of variability of samples. Furthermore, the 
algorithm has a Mfold cross-validation step to mask 
out outliers and gives control on the tuning of the 
number of components to achieve the best perfor-
mance. The CD patients and controls were all com-
pared. A model with two components was chosen: 
this had a classification error rate >41% 
(Mahalanobis distance, Supplemental material 3, 
Figure S7). Because of the high error rate these 
results were not presented. The second analysis 
compared CD patients in relapse and controls. The 
BER (balanced error rate) was lower than that in the 
previous comparison (around 34%, Supplemental 
material 3, Figure S8). Bacterial and metabolomics 
data were the best to discriminate between the two 
groups (Supplemental material 3, Figure S9-A) and 
showed the highest correlation for both components 
1 and 2 (Supplemental material 2, Figure S9-B1 and 
B2). In CD in relapse, the Circo plot correlations 
(Supplemental material 3, Figure S9-C) showed 
positive correlation between BCFA (2-methylbuta-
noic acid, 3-methylbutanoic acid and 2-methylpro-
panoic acid) with fungal OTUs assigned to 
Saccharomyces. OTUs assigned to Pichia, Candida 
and Aspergillus (higher in controls) were negatively 
correlated with both Saccharomyces and BCFA 
(higher in active CD). Saccharomyces OTUs and 
BCFA were also positively correlated to many bac-
terial OTUs assigned to Hafnia, Proteus, 
Lachnoclostridium, Lactobacillus, Proteus etc. 
(Supplemental material 3, Figure S9-C).
A third integration was done by combining the 
micro- and myco-biome data from the transverse 
colon mucosa and VOCs from stool (Figure 7). CD 
patients were compared with controls. The lowest 
error rate (34%) was obtained with 1 component 
(Mahalanobis distance, Supplemental material 3, 
Figure S10). The bacterial community, followed by 
the metabolome, was the best dataset to discriminate 
between the two categories (Figure 7-A). The features 
from component 1 allowed the separation of the two 
groups for all three datasets (Figure 7-B). These fea-
tures are presented in Figure 7-C. The majority of the 
bacterial OTUs found by this analysis were also 
implicated in taxa differential analysis and BV-STEP 
analysis. In particular, OTU2656 (B. thetaiotamicron, 
Figure 2-B). The fungal OTUs that were discriminant 
in component 1 space (Figure 7-C) were assigned to 
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Malassezia and Eurotiales (increased in CD) and 
Candida (increased in control). Only one metabolite 
was included in this component: 3-methylbutanoic 
acid. Correlations of variables of different datasets are 
between 3-methylbutanoic acid and most of the bac-
terial OTUs increased in CD (positive correlations), 
including OTU2656 Bacteroides. Candida OTUs 
were negatively correlated to most of the bacterial 
OTUs increased in CD (including OTU2656 
B. thetaiotamicron) and positively correlated to 
those increased in control (Supplemental material 2, 
Table S7).
Discussion
This study is the first to investigate the microbiome 
and the mycobiome from stool and biopsies, and 
the fecal volatile metabolome in parallel in patients 
with Crohn’s disease and controls. These three 
datasets were integrated with a statistical proce-
dure, that allows a consolidated view of multi- 
omics datasets. An optimized protocol32 was used 
for the investigation of fungal communities and 
standardized approaches to the microbiome41 and 
metabolome.42 We have clearly shown relation-
ships between volatile metabolites involved in the 
degradation of amino acids and intestinal micro-
biota in CD and found fungal species (Malassezia 
and Cyberlindnera) increased in CD that may have 
a role to play in the disease (e.g. pathogenesis or 
they thrive in inflammation).
The British cohort enabled us to integrate three 
omics datasets (matching disease and controls); in 
addition, paired biopsies and feces were available 
from many donors. In stool, the most abundant 
genus was Saccharomyces, followed by Candida, as 
already reported.43 The limited amount of fungal 
material observed in the mucosa suggests the wide-
spread presence of Saccharomyces in stool to the 
subjects’ dietary habits, as also recently suggested.44 
However, our multi-omics analysis has shown 
Saccharomyces increased in active CD as compared 
to controls and is positively correlated with some of 
the metabolites. A potential role of Saccharomyces 
in CD has been proposed,45 although this theory 
was quickly opposed by Sendid et al.46 and by the 
observation of S. cerevisiae reduced in active IBD 
and that it could actually be beneficial.12
Figure 7. Integration of metabolomics (volatile organic compounds, VOCs) and metagenomics (bacterial and fungi) data (Crohn’s 
disease (CD) vs Controls). 16S and 18S rRNA datasets were from transverse colon biopsy samples, and VOCs from stool samples. 
Samples groups were CD (n = 9) vs Controls (n = 7). A three omics sample plots are shown separately. B Pearson’s correlation of the 
three data set for component 1. C variables contributing to component 1.
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In stool (British cohort), a decrease of Candida 
abundance in CD patients was observed. This is in 
contrast to the current literature11–13 (and that 
observed in the Dutch cohort) that show Candida 
increased in IBD; we relate our observation to the 
small size of the cohort. However, we identified the 
negative correlation between Candida and 
B. thetaiotamicron (Bt), and we might speculate 
that the low abundance of Candida is related to 
the presence of Bt in the British cohort. Others 
have reported that Bt is able to prevent Candida 
colonization.27 A recent study also showed in 
a mouse model how Bt actually eliminates 
Candida species through enzymatic degradation.47 
Evidence for inter-kingdom relationships is shown 
by the increase in Ascomycota and decrease of 
Bacteroidetes observed in cirrhotic patients that is 
predictive of hospitalization within 90 days.48 We 
believe that the inter-kingdom relationship 
between Candida and Bacteroides in IBD requires 
further exploration.
Malassezia was increased in the colonic mucosa 
but reduced in the stool samples of CD patients 
(British cohort). It was increased in CD patients 
from the Dutch cohort. Suhr et al. 201549 reported 
that Malassezia is often found in stool and it is 
probably able to grow in the intestine.50 Further 
evidence comes from a recent study that showed 
Malassezia increased in the colonic mucosa of CD 
patients and that it exacerbated colitis in mice.18 
Our observation of an increase of this yeast within 
the colon of CD patients supports the findings of 
this earlier study suggesting further research oppor-
tunities to clarify Malassezia’s role in CD.
In the Dutch cohort (Figure 5-D and supplemen-
tal material 6) Candida abundance increased with 
the disease (CD vs HC at baseline), meanwhile, 
Saccharomyces decreased, in agreement with earlier 
reports.11–13 Incorporating explanatory variables, 
that is, medication, has shown that variation in 
the fungal community at baseline can be explained 
by two medications: immunosuppressants and bio-
logics. Patients who took immunosuppressants had 
significantly more Candida (OTU and genus level) 
and more Malassezia (genus level) (Figure 5-D2 
and Supplemental material 6), although its abun-
dance was low. Candidiasis are not uncommon in 
IBD patients treated with immunosuppressants,51 
however, the mechanisms of how these classes of 
medications influence the fungal community is 
unknown. The temporal analysis of CD cohort 
has shown that the fungal community is less stable 
in CD patients and this was significant for patients 
who achieved remission. However, RA patients had 
a less variable community (lower beta-dispersion) 
when compared to patients achieving remission. 
We also observed that when they transitioned 
from remission to relapse, Cyberlindnera increased. 
An increase of Cyberlindnera during relapse has 
been previously reported.16
The analysis of the fungal community in the two 
cohorts has highlighted some discrepancies. 
Differences in diet, the use of healthy controls in 
the Dutch cohort, opposed to non-IBD individuals 
referred to gastroenterology clinic in the British 
cohort, and differences in the DNA extraction 
method may account for some of these. The 
British cohort also had fewer samples and the lack 
of separation between CD and controls in stool 
samples may be because the study was underpow-
ered. However, even studies with a higher sampling 
struggled to find a separation between CD and 
controls, as was reported only when IBD and con-
trols were compared.12
A dysbiosis of the bacterial community was 
observed both in the feces and biopsies of CD 
patients (British cohort), who were more dysbiotic 
than UC, as expected.52 The CD microbiome had 
lower alpha diversity estimates, formed a separate 
cluster in beta-diversity analysis, and was found to 
be more phylogenetically similar. Both the pathogen-
esis of CD and its distribution contributed to the 
variability in the microbiome. Disease distribution 
explains 15% of the diversity and there was a clear 
separation of CD patients with and without ileal 
involvement (Figure 1-B3). Other factors also influ-
enced the microbiome composition (PERMANOVA 
analysis); the strongest predictor being patient ID, 
showing that the community was conserved in the 
mucosa and feces within an individual (R2 up to 
79%). A similar pattern of samples originating from 
the same subject has been observed previously.53 The 
site of the biopsy was less relevant (circa 6%) (Figure 
1-B4 and table in B2, Bray-Curtis distance). Extrinsic 
parameters (including clinical data) were also impli-
cated in explaining the variability in the microbiome 
structure: in particular BMI, age, ASCA antibodies 
and some medications. However, it is difficult to 
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confirm these influences as the CD patients were 
younger, leaner and more likely to have ASCA anti-
bodies, as compared to UC and control subjects 
(Table 1). Therefore, these interpretations should 
be approached with caution. Drugs, including mesa-
lamine and immunosuppressants54 can influence the 
gut microbiome.55 Mesalamine is taken by the 
majority of the patients with UC (15/20, Table 1) 
and we are unable to separate the influence of UC 
and mesalamine treatment. However, mesalamine 
has been shown to influence microbial metabolism 
and to reduce bacterial colonization of the mucosa.56
Taxa differential analysis has shown a reduction 
of Faecalibacterium in the colon and feces in CD, 
which is in agreement with other studies.52 Other 
microorganisms considered beneficial were also 
reduced in the colon and feces of CD 
patients: Roseburia16 and Methanobrevibacter. 
Lachnoclostridium was increased in CD, in every 
mucosa site and in the feces. L. bolteae (previously 
known as Clostridium bolteae), was proposed as 
a marker of dysbiosis related to the use of 
antibiotics57 and inflammation;58 however, it was 
decreased in CD pediatric patients.8 Further studies 
are indicated to clarify its role in dysbiosis and CD.
Bacteroides OTUs have shown mixed trends as 
some were increased in the mucosa of CD patients, 
although others were reduced. We found that 
B. thetaiotamicron (Bt) was increased in the colonic 
mucosa of CD patients (British cohort). Bt is crucial 
to the maturation of the gut immunity59 and 
microbiota,60 however, it can also have deleterious 
effects in the gut.61–63 Its interaction with 
F. prausnitzii (Fp) is particularly relevant in gut 
homeostasis; Bt prepares the gut environment for 
Fp to colonize, by reducing the redox potential;60 at 
the same time, Fp counterbalances and attenuates 
Bt effects in the gut.60 The decrease of Fp is likely to 
be one of the main events during dysbiosis and it is 
related to the increase in redox potential in the 
gut.64,65 Our observation of an increase of Bt and 
a simultaneous decrease of Fp in the colon of CD 
patients confirms that reduction of the latter actu-
ally causes the dysbiosis; a loss of Fp means that not 
only its anti-inflammatory action is lost,66 but also 
its counterbalancing effect on Bt. Moreover, the 
host susceptibility is likely to be a key factor in Bt 
impact in IBD.61–63
B. vulgatus was amongst the representative 
OTUs being part of the subsets that best correlated 
with the whole OTUs table (Supplemental material 
2, Tables S2). OTUs assigned to this species were 
highly abundant in CD and controls. Both mechan-
istic and observational studies have shown that it 
causes inflammation only in susceptible hosts.63,67 
Metatranscriptomic analysis shows that this is 
active in IBD patients.68
A final note on Bacteroides OTUs, many were 
part of the subsets obtained with the BV-STEP 
analysis, whose variability could be explained by 
calprotectin and increased in CD biopsies, showing 
a link between Bacteroides and inflammation, 
observed also by others.69,70
The analysis of VOCs in stool has shown an 
increase of metabolites associated with active CD,5 
that is, 3,7-dimethylocta-1,6-dien-3-ol; nonanal; 
2-methylpropyl butanoate; propyl 2-methyl pro-
panoate; propyl propanoate. 3,7-dimethylocta- 
1,6-dien-3-ol is a monoterpene in culinary herbs 
and produced by some fungi,37 including 
Saccharomycetales yeasts.39 Nonanal is an alde-
hyde, and these molecules are often increased in 
CD: we reported this both in human CD29 and in 
a mouse model of IBD.71 This has been linked to 
inflammation and oxidative stress;5 in this context, 
these molecules are produced endogenously during 
a non-enzymatic lipid peroxidation.72
The observation of other compounds is less con-
sistent with previously published literature, as these 
were actually proposed as discriminatory com-
pounds for healthy subjects: indole; butanoic acid; 
2-methylbutanoic acid; 3-methylbutanoic acid; 
2-methylpropanoic acid; 2-pentanone.5 Other stu-
dies confirm our observation that indole increases 
in CD.73,74 Indole is produced during the catabo-
lism of tryptophan by bacteria in the distal colon, in 
the presence of the free amino acid and absence of 
carbohydrates.75,76 SCFA (short chain fatty acid) 
are commonly produced in the colon during fiber 
degradation. In contrast, BCFA are exclusively pro-
duced by fermentation of branched-chained amino 
acids in the distal colon.76 Their increase in CD, 
observed here and by others,74 may be related to an 
increase in the fermentation of host amino acids 
obtained from luminal blood, mucins and inflamed 
tissue.73 Marchesi et al. linked the presence of 
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amino acids (including the precursors of BCFA) in 
the colon of CD patients to malabsorption77 .
The integration of the mucosa associated micro- 
and myco-biome and VOCs from stool of the 
British cohort was the most informative of the 
three cases considered. It confirmed Bt to be 
a signature feature in the mucosa of CD patients. 
This was positively correlated to 3-methylbutanoic 
acid and negatively correlated with Candida. These 
analyses have also shown Malassezia as a diagnostic 
modality to discriminate between the CD and con-
trols cohort.
The comparison of active CD patients and con-
trols cohort has shown that OTUs assigned to 
Sacchromycetales yeasts were correlated with 
BCFA, suggesting that these strains may be meta-
bolically active. S. cerevisiae can produce this mole-
cule by valine degradation.78 2-pentylfuran was also 
correlated with Saccharomycetales OTUs. 
Production of aldehydes can occur spontaneously 
during oxidative stress and may indicate inflamma-
tion rather than the activity of fungi;79 however, it 
may be consumed in some foods including soy 
milk80 and cheese production.81
Results of the comparison of all CD patients vs 
control were not included because the model gave 
an high error rate (close to 50%). This was likely 
related to the small sample size and to the high 
variability within the groups, due to many factors, 
such as the distribution and status of the disease.
To summarize, the use of Mixomics to integrate 
microbial with metabolomics data has shown that 
there is an increase of amino acid degradation in 
CD patients. Some of the VOCs were correlated 
with specific bacteria in addition to fungi in CD 
patients. This suggests that 1) fungi might be meta-
bolically active in relapsing CD patients, 2) the 
degradation of amino acids is associated with CD 
and fungi might be involved in this. In the mucosa, 
this analysis confirmed that Bt and Malassezia are 
the representative features in CD. The role of Bt in 
controlling Candida colonization warrants further 
investigation.
There are some limitations in our study. The 
British cohort was relatively small which caused 
two issues: the analysis of the mycobiome did not 
support the hypothesis that it changes in diseased 
patients; the second issue was related to the multi- 
omics integration algorithm; the small cohort size 
gave a high BER that limits our ability to draw 
conclusive interpretations from our results. It is 
recently demonstrated that most of the mycobiome 
observed in the stool of healthy individuals is from 
food or the mouth,44 with the only exception of 
C. albicans, the only colonizer found so far in 
healthy individuals.82 This was also confirmed in 
our study, as we observed fungi only in a fraction of 
mucosa samples. In stool, the presence of fungi 
from the diet makes it difficult to discriminate 
between the mycobiota and fungi that are simply 
in transit. A recent study confirmed this discre-
pancy between mycobiome profiles from stool 
compared to biopsies, showing that Debaryomyces 
was prevalent (and viable) in the inflamed mucosa, 
but not in non-inflamed tissue or stool samples 
from the same individual.20 The use of a multi- 
omics approach may partially solve this issue, as 
the correlation of fungi with metabolites can be an 
indication of their activity, although a higher sam-
ple size is required in order to reduce the error rate 
and get more reliable correlations. The analysis of 
the transcriptome instead of the metagenome as 
a template for mycobiome analysis, coupled with 
metabolomics analysis, may overcome this issue 
altogether. Nonetheless, we have shown that an 
integrative approach such as the one considered 
in this study, informed by the latest in multivariate 
statistics, should be able to divulge underlying bio-
logical mechanisms that not otherwise possible by 
analyzing these datasets in isolation. Criticisms 
may rise by the use of 18S rRNA as target gene for 
the analysis of the mycobiome instead of the more 
commonly used ITS; however, we have already 
shown its efficacy in discriminating taxa relevant 
to the human gut.32
These data add a new layer of complexity to the 
microbial community in the intestine. Fungi reside 
in the mucosa and appear to interact with the 
bacterial community – especially Bacteroides. 
Mining these interactions is key to understanding 
the role of fungi on the disease and will lead to new 
potential therapies, i.e. manipulation of the 
microbiome28 informed by the individual micro- 
and myco-biota (personalized medicine). Our 
study did not show a direct link between fungi 
and CD, However, as discussed by Richard et al.28 
only when specific opportunistic fungi are present, 
these appear to have a role in the severity of 
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inflammation. Therefore, the use of antifungal and 
antibacterial agents should be used with care; and it 
is worth remembering that many drugs have off- 
target effects that act on microbes.55,83,84 Another 
aspect of our study was the integration of fungal 
and bacterial datasets with VOCs metabolomics 
data. We are aware that the small cohort did not 
allow to draw definite conclusions on the involve-
ment of fungi in the production of fungal 
metabolites.5 However, we firmly believe that by 
carrying out integrated analysis on larger cohorts 
or on cohorts of patients with a confirmed fungal 
involvement, we will be able to show this direct link 
VOCs-fungi and to produce a very powerful diag-
nostic method that would greatly facilitate the 
application of personalized treatments.
In conclusion, our findings suggest that i) some 
fungal species, not only Candida but also 
Malassezia and Cyberlindnera, are likely to have 
a role in the pathogenesis and/or course of CD. 
Immunosuppression may increase Candida and 
Malassezia colonization in CD patients, ii) the low 
abundance of fungi in the mucosa means that fungi 
are not involved in all CD patients, iii) Bacteroides 
strains play a substantial role in CD and may mod-
ulate Candida colonization, and iv) amino acid 
degradation is associated with CD, and we identi-
fied bacterial and fungal species involved in their 




This was an observational study of two cohorts 
from different geographic areas in Liverpool, UK, 
and Maastricht, The Netherlands. Patients 
recruited at the Royal Liverpool University 
Hospital (UK), between August 2015 and 
May 2017, were part of the European Union 
Seventh Framework Programme (EU-FP7) funded 
SysMedIBD (Systems Medicine of chronic 
Inflammatory Bowel Disease) Project (https:// 
www.sysmedibd.eu/); they had CD or UC, or 
were non-IBD patients referred to the gastroenter-
ology clinic who underwent diagnostic colono-
scopy (controls). Demographic and clinical data 
including the diagnosis, disease phenotype 
(Montreal classification) and fecal calprotectin 
were collected. Donors from Maastricht were 
part of the Inflammatory Bowel Disease South 
Limburg Cohort (IBDSL) (The Netherlands):85 
they included CD patients and healthy controls 
who were followed-up and sampled at least 
twice. All donors gave written informed consent 
before they were enrolled in the studies in accor-
dance with ethical approval (reference 15/NW/ 
0045 (Liverpool) and NL24572.018.08 (South 
Limburg)).
Specimens
The British cohort stool samples were collected at 
home, stored chilled and brought to the hospital on 
the same day, or after overnight storage. Samples 
for DNA extraction were aliquoted immediately, 
transferred to the laboratory and stored at −80°C. 
Aliquots for VOCs analysis by gas chromatography 
mass spectrometry (GC-MS) were stored at −20°C. 
Biopsies of the ileum and colon were flash frozen in 
liquid nitrogen immediately, brought to the labora-
tory and stored at −80°C for later DNA extraction. 
Blood samples were collected in heparinized vials at 
5 U/mL (Wockhardt UK Ltd; Wrexham; Wales): 
plasma was collected and stored at −20°C for later 
enzyme-linked immunosorbent assay (ELISA) for 
ASCA.
Only fecal samples were collected from the 
Dutch cohort: their collection and processing, 
including DNA extraction, performed with 
a modified protocol of the PSP stool DNA kit 
(Stratec), has been described in detail elsewhere:34 
the extracted DNA was sent to the Liverpool 
laboratory for mycobiome studies.
DNA extraction
Stool samples, from British subjects, were extracted 
using two kits to maximize extraction of fungal 
DNA, specifically a modified version of the PSP 
stool DNA kit (Stratec), and the QIAamp Fast 
DNA Stool mini kit (QIAGEN), details are 
described in Frau et al.32 DNA was extracted from 
the biopsies with the QIAamp cador Pathogen Mini 
Kit (Pretreatments T2, B1) (QIAGEN, Manchester, 
UK); it was quantified and normalized for down-
stream analysis as for feces.32
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Amplicons sequencing
Fungal 18S rRNA amplicons were sequenced for 
both cohorts, while bacterial 16S rRNA amplicons 
were sequenced only for the British cohort. 
A 2-step PCR universal tail tag dual index barcod-
ing approach was used.41 Fungal amplicons were 
generated as previously described.32 For bacterial 
16S rRNA gene (V4 region) sequencing, the 
method described by D’Amore et al.41 was used 
with a modified forward primer (Supplemental 
material 1, Table S1). Details are in the 
Supplemental material 1 (Supplementary 
Methods).
VOCs
VOCs were analyzed following the method by 
Reade at al.42 Frozen stool samples were aliquoted 
(450–500 mg) and dispensed in 10 mL vials. VOCs 
were extracted from the headspace using 
a divinylbenzene-carboxen-polydimethylsiloxane 
solid-phase micro-extraction fiber (Sigma-Aldrich, 
Dorset, UK) and analyzed in a PerkinElmer Clarus 
500 GC/MS quadrupole benchtop system 
(Beaconsfield, UK) fitted with a 60 m Zebron ZB- 
624 column (inner diameter 0.25 mm, length 60 m, 
film thickness 1.4 μm (Phenomenex, Macclesfield, 
UK)).42 Chromatograms were analyzed with 
Automated Deconvolution System (AMDIS) using 
the NIST mass spectral library to identify the peaks. 
This library included compounds related to fungi 
and CD markers.5 Statistical analysis was per-
formed in Metaboanalyst,86 adjusting first the NA 
values to half of the minimum value for each com-
pound and normalization by log transform (glog) 
and Pareto-scaling was performed, and reported 
using partial least squares discriminant analysis.
ASCA ELISA
Anti-Saccharomyces cerevisiae antibody ELISA 
(IgG) was carried out with a commercial kit 
(EUROIMMUN cat. EV 2841–9601 G, Luebeck, 
Germany) using plasma samples which were ana-
lyzed in triplicate.
All experimental procedures were carried out 
following manufacture’s protocols and risk assess-
ments were produced.
Bioinformatics and statistical analysis




For specimens collected in Liverpool (UK), the 
ethical approval for the use of stool samples 
(SysMedIBD; EU-FP7 project, under grant agree-
ment no. 305564) was granted by NRES Committee 
North West – Liverpool East, reference (15/NW/ 
0045). For the specimens collected in the 
Netherlands (Inflammatory Bowel Disease South 
Limburg Cohort (IBDSL) (The Netherlands)), ethi-
cal approval was given by the Medical Ethics 
Committee of Maastricht University Medical 
Center and was executed according to the revised 
Declaration of Helsinki (59th General Assembly of 
WMA, Seoul, South Korea, Oct. 2008). The study 
has been registered in the Central Committee on 
Research Involving Human Subjects (CCMO) reg-
istry under file number NL24572.018.08.
Availability of data and materials
The datasets of the sequencing raw reads support-
ing the conclusions of this article are available in 
the European Nucleotide Archive, under study 
accession numbers: PRJEB38969 (16S rRNA, stool 
and biopsy samples, British cohort), PRJEB29083 
and PRJEB39119 (18S rRNA, stool samples, British 
cohort), PRJEB39016 (18S rRNA, biopsy samples, 
British cohort), PRJEB39063 (18S rRNA, stool sam-
ples, Dutch cohort).
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